SPI Healthcare
3.597,97
PKT
+5,14
PKT
+0,14
%
Werbung
Leider sind zu diesem Wert keine aktuellen Kursdaten verfügbar, die Stammdaten finden Sie im unteren Seitenbereich.
Analysen zu SPI Healthcare-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 25.07.12 | Lonza neutral | Sarasin Research | |
| 25.07.12 | Novartis buy | Nomura | |
| 25.07.12 | Novartis kaufen | Sarasin Research | |
| 25.07.12 | Lonza hold | Vontobel Research | |
| 23.07.12 | Basilea Pharmaceutica hold | Vontobel Research | |
| 23.07.12 | Novartis hold | Vontobel Research | |
| 23.07.12 | Novartis outperform | Sanford C. Bernstein and Co., Inc. | |
| 20.07.12 | Novartis buy | Société Générale Group S.A. (SG) | |
| 20.07.12 | Novartis kaufen | Hamburger Sparkasse AG (Haspa) | |
| 20.07.12 | Novartis hold | Vontobel Research | |
| 20.07.12 | Novartis neutral | Exane-BNP Paribas SA | |
| 19.07.12 | Novartis halten | Independent Research GmbH | |
| 19.07.12 | Novartis buy | Sarasin Research | |
| 19.07.12 | Novartis hold | Vontobel Research | |
| 19.07.12 | Novartis hold | Vontobel Research | |
| 19.07.12 | Novartis buy | Société Générale Group S.A. (SG) | |
| 18.07.12 | Novartis neutral | Exane-BNP Paribas SA | |
| 17.07.12 | Novartis buy | Deutsche Bank AG | |
| 17.07.12 | Novartis buy | Société Générale Group S.A. (SG) | |
| 17.07.12 | Novartis buy | UBS AG | |
| 13.07.12 | Novartis buy | Nomura | |
| 13.07.12 | Novartis kaufen | Fuchsbriefe | |
| 12.07.12 | Novartis neutral | J.P. Morgan Cazenove | |
| 12.07.12 | Novartis outperform | Credit Suisse Group | |
| 12.07.12 | Novartis hold | Vontobel Research | |
| 12.07.12 | Novartis neutral | Citigroup Corp. | |
| 11.07.12 | Novartis neutral | J.P. Morgan Cazenove | |
| 10.07.12 | Sonova neutral | Sarasin Research | |
| 05.07.12 | Novartis buy | Deutsche Bank AG | |
| 28.06.12 | Novartis buy | Deutsche Bank AG | |
| 28.06.12 | Novartis outperform | Sanford C. Bernstein and Co., Inc. | |
| 25.06.12 | Novartis neutral | UBS AG | |
| 25.06.12 | Novartis buy | UBS AG | |
| 25.06.12 | Sonova buy | Vontobel Research | |
| 22.06.12 | Novartis outperform | Credit Suisse Group | |
| 22.06.12 | Lonza outperform | Cheuvreux SA | |
| 19.06.12 | Novartis neutral | J.P. Morgan Cazenove | |
| 19.06.12 | Novartis neutral | Exane-BNP Paribas SA | |
| 14.06.12 | Straumann underperform | Cheuvreux SA | |
| 13.06.12 | Basilea Pharmaceutica hold | Vontobel Research |